Wire · opportunities
FDA Expands Accelerated Approval of Sevabertinib to First-Line HER2-Mutant NSCLC
◆ Sectors
Drug Discovery
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
The FDA has expanded the accelerated approval of sevabertinib to include first-line treatment for patients with HER2-mutant non-small cell lung cancer (NSCLC), potentially broadening access to this targeted therapy.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 7 sources have reported it.
◆ ◆ The Wire takeaway
You can now address a larger group of lung cancer patients with HER2 mutations due to FDA's wider approval of sevabertinib, opening new patient markets this quarter.
◆ Coverage
7 sources · 9 Sep 2026
◆ Related on Wire
◆ Topics
Drug DiscoveryFDA-approvalcancerNSCLCHER2-mutantoncology